Graf Acquisition Corp. IV
Status: Closed Deal
U=S+W/5
W=S@11.50
| IPO Proceeds, $M | $171.62M |
|---|---|
| IPO Date | May 21, 2021 |
| CEO | James A. Graf |
| Left Lead | JP Morgan |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 + 4 |
| IPO Sector | General ▶ |
| IPO Geography | Global |
| Target Company | NKGen Biotech |
| Deal Announced | Apr 14, 2023 |
| Deal Size, $M | $184.90M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Sep 25, 2023 |
| Amendment Vote | May 22, 2023 |
| Closing Date | Sep 29, 2023 |
Formerly GFOR
NKGN
NKGNW
| Price | $0.14 |
|---|---|
| Last closing price | $0.19 |
| H/L, today | $0.14 / $0.18 |
| H/L, 52-week | $2.80 / $6.70 |
| Volume, today | 50,712 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.